Explore

Trendline Trendline
Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone
Trendline Trendline
Stoke Therapeutics Reports Positive Data on Zorevunersen for Dravet Syndrome

Stoke Therapeutics Reports Positive Data on Zorevunersen for Dravet Syndrome

Stoke Therapeutics Reports Positive Data on Zorevunersen for Dravet Syndrome
Trendline Trendline
Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors

Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors

Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors
Trendline Trendline
Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD

Epicrispr Biotechnologies Partners with Forge Biologics for Gene Therapy Trials in FSHD
Trendline Trendline
FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change

FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change

FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change
Trendline Trendline
FDA to Reconsider Rejection of Ebvallo Cell Therapy for Rare Disease

FDA to Reconsider Rejection of Ebvallo Cell Therapy for Rare Disease

FDA to Reconsider Rejection of Ebvallo Cell Therapy for Rare Disease
Trendline Trendline
DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke

DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke

DiaMedica Therapeutics Reports Financial Results and Advances Clinical Trials for Preeclampsia and Stroke
Trendline Trendline
ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Advancements in AI and Genomics Propel Personalized Medicine Market to USD 1,397.63 Billion by 2035

Advancements in AI and Genomics Propel Personalized Medicine Market to USD 1,397.63 Billion by 2035

Advancements in AI and Genomics Propel Personalized Medicine Market to USD 1,397.63 Billion by 2035